149 related articles for article (PubMed ID: 32080088)
41. State of Radiomics in Glioblastoma.
Taha B; Boley D; Sun J; Chen CC
Neurosurgery; 2021 Jul; 89(2):177-184. PubMed ID: 33913492
[TBL] [Abstract][Full Text] [Related]
42. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
[TBL] [Abstract][Full Text] [Related]
43. Quantitative texture analysis in the prediction of IDH status in low-grade gliomas.
Jakola AS; Zhang YH; Skjulsvik AJ; Solheim O; Bø HK; Berntsen EM; Reinertsen I; Gulati S; Förander P; Brismar TB
Clin Neurol Neurosurg; 2018 Jan; 164():114-120. PubMed ID: 29220731
[TBL] [Abstract][Full Text] [Related]
44. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
45. The Value of Immunohistochemical Methods and Preoperative Magnetic Resonance Imaging Findings in Diagnosis of IDH1 Mutant Glioblastomas.
Kiraz U; Vural C; Turan G; Alparslan B; Dervisoglu E
Turk Neurosurg; 2022; 32(2):228-236. PubMed ID: 34859824
[TBL] [Abstract][Full Text] [Related]
46. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
47. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
[TBL] [Abstract][Full Text] [Related]
48. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
[TBL] [Abstract][Full Text] [Related]
49. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
50. Noninvasive Determination of
Bhandari AP; Liong R; Koppen J; Murthy SV; Lasocki A
AJNR Am J Neuroradiol; 2021 Jan; 42(1):94-101. PubMed ID: 33243896
[TBL] [Abstract][Full Text] [Related]
51. Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging.
Li Y; Liang Y; Sun Z; Xu K; Fan X; Li S; Zhang Z; Jiang T; Liu X; Wang Y
Neuroradiology; 2019 Nov; 61(11):1229-1237. PubMed ID: 31218383
[TBL] [Abstract][Full Text] [Related]
52. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
53. Comparison of Immunogenetic Properties of Glial Tumors with Advanced Magnetic Resonance Imaging Findings.
Gezer B; Mutlukan A; Sahinoglu M; Karabagli PN; Koktekir E; Karabagli H
Turk Neurosurg; 2020; 30(3):422-427. PubMed ID: 32091123
[TBL] [Abstract][Full Text] [Related]
54. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
[TBL] [Abstract][Full Text] [Related]
55. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
56. Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
Ishi Y; Yamaguchi S; Okamoto M; Sawaya R; Endo S; Motegi H; Terasaka S; Tanei ZI; Hatanaka KC; Tanaka S; Fujimura M
Brain Tumor Pathol; 2022 Jul; 39(3):162-170. PubMed ID: 35362874
[TBL] [Abstract][Full Text] [Related]
57. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
58. The Value of Enhanced MR Radiomics in Estimating the IDH1 Genotype in High-Grade Gliomas.
Niu L; Feng WH; Duan CF; Liu YC; Liu JH; Liu XJ
Biomed Res Int; 2020; 2020():4630218. PubMed ID: 33163535
[TBL] [Abstract][Full Text] [Related]
59. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
60. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]